News
Nicolas Ferreyros discusses the Community Oncology Alliance’s position statements on biomarker testing and physician autonomy.
A phase 1/2 trial of CRISPR-engineered eTIL therapy KSQ-004EX for advanced solid tumors has dosed its first patient.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback